Hemolysis and methemoglobinemia secondary to rasburicase administration

Annals of Pharmacotherapy

Volumn 39, Issue 11, 2005, Pages 1932-1935

  Browning, Linda A ^a   Kruse, James A ^b  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b BASSETT MEDICAL CENTER   (United States)

Author keywords

Glucose 6 phosphate dehydrogenase deficiency; Hemolytic anemia; Methemoglobin; Rasburicase; Uric acid

Indexed keywords

HEMOGLOBIN; METHEMOGLOBIN; RASBURICASE;

ACUTE KIDNEY FAILURE; ADULT; ARTERIAL GAS; ARTICLE; ASSISTED VENTILATION; BLOOD GAS ANALYSIS; BLOOD TRANSFUSION; CASE REPORT; CONCENTRATION RESPONSE; DIABETIC KETOACIDOSIS; DRUG CONTRAINDICATION; ENZYME THERAPY; FLUID THERAPY; GLYCOGEN STORAGE DISEASE TYPE 1; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HUMAN; HYPERURICEMIA; MALE; METHEMOGLOBINEMIA; PRIORITY JOURNAL; PROBABILITY; RESPIRATORY FAILURE; RISK ASSESSMENT; SEIZURE; TUMOR LYSIS SYNDROME;

ANEMIA, HEMOLYTIC; BLOOD TRANSFUSION; FLUID THERAPY; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHEMOGLOBINEMIA; MIDDLE AGED; RESPIRATION, ARTIFICIAL; STATUS EPILEPTICUS; TREATMENT OUTCOME; TREMOR; URATE OXIDASE;

EID: 27344455353     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G272     Document Type: Article

References (14)

1. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003;37:1047-54. DOI 10.1345/aph.1C336
2. Package insert. Elitek (rasburicase). New York: Sanofi-Synthelabo, March 2004.
3. Pui C-H, Jeha S, Irwin D, Camilla B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15:1505-9. DOI 10.1038/st.jeu.2402235
4. Navolanic PM, Pui C-H, Larson RA, Bishop MR, Pearce TE, Cairo MS, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003;17:499-514. DOI 0.1038/sj.leu.2402847
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
6. Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 1991;324:169-74.
7. Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med 1999;34:646-56.
8. Pui C-H, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697-704.
9. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98:1048-54. DOI 10.1002/cncr.11612
10. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003. DOI 10.1182/blood.v97.10.2998
11. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21:4402-6. DOI 10.1200/JCO.2003.04.115
12. van den Berg H, van de Wetering AM, Reintsema PA. Prevention of hyperuricemia with urate oxidase (rasburicase) in children during chemotherapy induction (abstract). Blood 2001;98:112a.
13. Schlesinger N. Management of acute and chronic arthritis. Drugs 2004;64:2399-416.
14. Ducros J, Saingra S, Rampal M, Coulange C, Barbe MC, Verzetti G. Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol 1991;35:89-90.